Please assess the completion status of the following clinical trial:

Trial Title: StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age and less than 65 years of age~* BMI of at least 35 and no more than 40~* At least 2 years post-RNYGB surgery~* Initially achieved at least 60% EBL and a BMI 35 or less~* Regained at least 20% of pre-RNYGB excess weight at screening~* Stable weight or continued failure to lose weight for at least 3 months~* Enlarged gastric pouch (≥ 30 ml)~* Anatomy of upper GI judged suitable for revision using StomaphyX~* Completed successful nutritional screening~* Normal levels of vitamin D, iron/ferritin, calcium, and magnesium~* Absence of protein malnutrition confirmed by serum albumin \> 3 g/dL~* Willing to cooperate with follow-up dietary recommendations and assessment tests~* Signed Informed Consent~Exclusion Criteria:~* Previous revisional bariatric surgery after RNYGB~* Esophageal stricture or any anatomic condition that precludes passage of the StomaphyX device to the gastric pouch~* Diabetes type I~* Causal factors for weight regain other than gastric pouch enlargement~* Serious complications experienced during and/or after RNYGB such as leaks, fistula, incisional hernia, ulcers, pulmonary embolism or deep venous thrombosis~* Pregnancy or plans of pregnancy in the next 12 months~* Immunosuppression~* ASA \> 3~* Life expectancy less than one year~* An eating disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Washington DC, American Psychiatric Association, 2000~* Active substance abuse~* Plans of smoking cessation in the next 12 months~* Treatment with weight-loss prescription drug therapy within three months preceding the screening~* Intention to use prescription drug therapy or the use of over-the-counter weight-loss preparations during the current study~* Current participant in another weight-loss study or other clinical trial~* Inflammatory bowel disease~* Presence of ulceration at the gastrojejunostomy anastomosis~* Portal hypertension~* Coagulation disorders or chronic use of anticoagulants~* Any active medical condition that would preclude the patient from completing the study or would result in an unreasonable risk to the patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- StomaphyX (Type: EXPERIMENTAL): Post-Roux-en-Y revisional surgery using the StomaphyX device.
- Sham Procedure (Type: SHAM_COMPARATOR): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).